Targeting GITR in cancer immunotherapy – there is no perfect knowledge

por Davar, Diwakar, Zappasodi, Roberta
Publicado 2023

Editorial: Factors determining long term anti-tumor responses to immune checkpoint blockade therapy

por Zappasodi, Roberta, Cook, Graham P., Taylor, Alison
Publicado 2022

Lymphoma Immunotherapy: Current Status

por Zappasodi, Roberta, de Braud, Filippo, Di Nicola, Massimo
Publicado 2015

Facts and Perspectives: Implications of tumor glycolysis on immunotherapy response in triple negative breast cancer

por Schreier, Ashley, Zappasodi, Roberta, Serganova, Inna, Brown, Kristy A., Demaria, Sandra, Andreopoulou, Eleni
Publicado 2023

Impairment of Treg suppression by GITR ligation is effective selectively in the context of a pro-inflammatory tumor microenvironment

por Zappasodi, Roberta, Budhu, Sadna, Schaer, David, Yang, Xia, Zhong, Hong, Merghoub, Taha, Wolchok, Jedd D
Publicado 2014

Epigenetic, Metabolic, and Immune Crosstalk in Germinal-Center-Derived B-Cell Lymphomas: Unveiling New Vulnerabilities for Rational Combination Therapies

por Serganova, Inna, Chakraborty, Sanjukta, Yamshon, Samuel, Isshiki, Yusuke, Bucktrout, Ryan, Melnick, Ari, Béguelin, Wendy, Zappasodi, Roberta
Publicado 2022

Therapeutic antibody activation of the glucocorticoid-induced TNF receptor by a clustering mechanism

por He, Changhao, Maniyar, Rachana R., Avraham, Yahel, Zappasodi, Roberta, Rusinova, Radda, Newman, Walter, Heath, Heidi, Wolchok, Jedd D., Dahan, Rony, Merghoub, Taha, Meyerson, Joel R.
Publicado 2022

Society for Immunotherapy of Cancer (SITC) consensus definitions for resistance to combinations of immune checkpoint inhibitors

por Kluger, Harriet, Barrett, J Carl, Gainor, Justin F, Hamid, Omid, Hurwitz, Michael, LaVallee, Theresa, Moss, Rebecca A, Zappasodi, Roberta, Sullivan, Ryan J, Tawbi, Hussein, Sharon, Elad
Publicado 2023

Targeting Phosphatidylserine Enhances the Anti-tumor Response to Tumor-Directed Radiation Therapy in a Preclinical Model of Melanoma

por Budhu, Sadna, Giese, Rachel, Gupta, Aditi, Fitzgerald, Kelly, Zappasodi, Roberta, Schad, Sara, Hirschhorn, Daniel, Campesato, Luis Felipe, De Henau, Olivier, Gigoux, Mathieu, Liu, Cailian, Mazo, Gregory, Deng, Liang, Barker, Christopher A., Wolchok, Jedd D., Merghoub, Taha
Publicado 2021

APR-246 increases tumor antigenicity independent of p53

por Michels, Judith, Venkatesh, Divya, Liu, Cailian, Budhu, Sadna, Zhong, Hong, George, Mariam M, Thach, Daniel, Yao, Zhong-Ke, Ouerfelli, Ouathek, Liu, Hengrui, Stockwell, Brent R, Campesato, Luis Felipe, Zamarin, Dmitriy, Zappasodi, Roberta, Wolchok, Jedd D, Merghoub, Taha
Publicado 2023

Fifteen-year follow-up of relapsed indolent non-Hodgkin lymphoma patients vaccinated with tumor-loaded dendritic cells

por Fucà, Giovanni, Ambrosini, Margherita, Agnelli, Luca, Brich, Silvia, Sgambelluri, Francesco, Mortarini, Roberta, Pupa, Serenella M, Magni, Michele, Devizzi, Liliana, Matteucci, Paola, Cabras, Antonello, Zappasodi, Roberta, De Santis, Francesca, Anichini, Andrea, De Braud, Filippo, Gianni, Alessandro M, Di Nicola, Massimo
Publicado 2021

Phase IB Study of GITR Agonist Antibody TRX518 Singly and in Combination with Gemcitabine, Pembrolizumab, or Nivolumab in Patients with Advanced Solid Tumors

por Davar, Diwakar, Zappasodi, Roberta, Wang, Hong, Naik, Girish S., Sato, Takami, Bauer, Todd, Bajor, David, Rixe, Olivier, Newman, Walter, Qi, Jingjing, Holland, Aliya, Wong, Phillip, Sifferlen, Lianna, Piper, Diane, Sirard, Cynthia A., Merghoub, Taha, Wolchok, Jedd D., Luke, Jason J.
Publicado 2022

Blockade of the AHR restricts a Treg-macrophage suppressive axis induced by L-Kynurenine

por Campesato, Luis Felipe, Budhu, Sadna, Tchaicha, Jeremy, Weng, Chien-Huan, Gigoux, Mathieu, Cohen, Ivan Jose, Redmond, David, Mangarin, Levi, Pourpe, Stephane, Liu, Cailian, Zappasodi, Roberta, Zamarin, Dmitriy, Cavanaugh, Jill, Castro, Alfredo C., Manfredi, Mark G., McGovern, Karen, Merghoub, Taha, Wolchok, Jedd D.
Publicado 2020

CD36-mediated metabolic adaptation supports regulatory T cell survival and function in tumors

por Wang, Haiping, Franco, Fabien, Tsui, Yao-Chen, Xie, Xin, Trefny, Marcel P., Zappasodi, Roberta, Mohmood, Syed Raza, Fernández-García, Juan, Tsai, Chin-Hsien, Schulze, Isabell, Picard, Florence, Meylan, Etienne, Silverstein, Roy, Goldberg, Ira, Fendt, Sarah-Maria, Wolchok, Jedd D., Merghoub, Taha, Jandus, Camilla, Zippelius, Alfred, Ho, Ping-Chih
Publicado 2020

CTLA-4 blockade drives loss of Treg stability in glycolysis-low tumors

por Zappasodi, Roberta, Serganova, Inna, Cohen, Ivan J., Maeda, Masatomo, Shindo, Masahiro, Senbabaoglu, Yasin, Watson, McLane J., Leftin, Avigdor, Maniyar, Rachana, Verma, Svena, Lubin, Matthew, Ko, Myat, Mane, Mayuresh M., Zhong, Hong, Liu, Cailian, Ghosh, Arnab, Abu-Akeel, Mohsen, Ackerstaff, Ellen, Koutcher, Jason A., Ho, Ping-Chih, Delgoffe, Greg M., Blasberg, Ronald, Wolchok, Jedd D., Merghoub, Taha
Publicado 2021

Tumor-induced double positive T cells display distinct lineage commitment mechanisms and functions

por Schad, Sara E., Chow, Andrew, Mangarin, Levi, Pan, Heng, Zhang, Jiajia, Ceglia, Nicholas, Caushi, Justina X., Malandro, Nicole, Zappasodi, Roberta, Gigoux, Mathieu, Hirschhorn, Daniel, Budhu, Sadna, Amisaki, Masataka, Arniella, Monica, Redmond, David, Chaft, Jamie, Forde, Patrick M., Gainor, Justin F., Hellmann, Matthew D., Balachandran, Vinod, Shah, Sohrab, Smith, Kellie N., Pardoll, Drew, Elemento, Olivier, Wolchok, Jedd D., Merghoub, Taha
Publicado 2022

Hallmarks of Resistance to Immune-Checkpoint Inhibitors

por Karasarides, Maria, Cogdill, Alexandria P., Robbins, Paul B., Bowden, Michaela, Burton, Elizabeth M., Butterfield, Lisa H., Cesano, Alessandra, Hammer, Christian, Haymaker, Cara L., Horak, Christine E., McGee, Heather M., Monette, Anne, Rudqvist, Nils-Petter, Spencer, Christine N., Sweis, Randy F., Vincent, Benjamin G., Wennerberg, Erik, Yuan, Jianda, Zappasodi, Roberta, Lucey, Vanessa M. Hubbard, Wells, Daniel K., LaVallee, Theresa
Publicado 2022

Increased p53 expression induced by APR-246 reprograms tumor-associated macrophages to augment immune checkpoint blockade

por Ghosh, Arnab, Michels, Judith, Mezzadra, Riccardo, Venkatesh, Divya, Dong, Lauren, Gomez, Ricardo, Samaan, Fadi, Ho, Yu-Jui, Campesato, Luis Felipe, Mangarin, Levi, Fak, John, Suek, Nathan, Holland, Aliya, Liu, Cailian, Abu-Akeel, Mohsen, Bykov, Yonina, Zhong, Hong, Fitzgerald, Kelly, Budhu, Sadna, Chow, Andrew, Zappasodi, Roberta, Panageas, Katherine S., de Henau, Olivier, Ruscetti, Marcus, Lowe, Scott W., Merghoub, Taha, Wolchok, Jedd D.
Publicado 2022

Defining tumor resistance to PD-1 pathway blockade: recommendations from the first meeting of the SITC Immunotherapy Resistance Taskforce

por Kluger, Harriet M., Tawbi, Hussein A., Ascierto, Maria L., Bowden, Michaela, Callahan, Margaret K., Cha, Edward, Chen, Helen X., Drake, Charles G., Feltquate, David M., Ferris, Robert L., Gulley, James L., Gupta, Shilpa, Humphrey, Rachel W., LaVallee, Theresa M., Le, Dung T., Hubbard-Lucey, Vanessa M., Papadimitrakopoulou, Vassiliki A., Postow, Michael A., Rubin, Eric H., Sharon, Elad, Taube, Janis M., Topalian, Suzanne L., Zappasodi, Roberta, Sznol, Mario, Sullivan, Ryan J.
Publicado 2020

Fundamental immune–oncogenicity trade-offs define driver mutation fitness

por Hoyos, David, Zappasodi, Roberta, Schulze, Isabell, Sethna, Zachary, de Andrade, Kelvin César, Bajorin, Dean F., Bandlamudi, Chaitanya, Callahan, Margaret K., Funt, Samuel A., Hadrup, Sine R., Holm, Jeppe S., Rosenberg, Jonathan E., Shah, Sohrab P., Vázquez-García, Ignacio, Weigelt, Britta, Wu, Michelle, Zamarin, Dmitriy, Campitelli, Laura F., Osborne, Edward J., Klinger, Mark, Robins, Harlan S., Khincha, Payal P., Savage, Sharon A., Balachandran, Vinod P., Wolchok, Jedd D., Hellmann, Matthew D., Merghoub, Taha, Levine, Arnold J., Łuksza, Marta, Greenbaum, Benjamin D.
Publicado 2022